Amgen's experimental weight loss injection, MariTide, showed up to 20% weight loss in patients without diabetes and 17% in ...

MariTide is being studied for the treatment of obesity and Type 2 diabetes and demonstrated weight loss at 52 weeks.

A new weight loss drug called MariTide caused 20 percent weight loss in a recent trial, even better than Wegovy or Ozempic.

In this edition of Law Talk, Attorney Megan Collins discusses the growing market for compounded weight-loss drugs and how you can stay safe when selecting certain medicines.

▎药明康德内容团队编辑今日，安进（Amgen）公布其在研减重疗法MariTide在一项为期52周的临床2期研究的积极结果。分析显示，在没有2型糖尿病的肥胖或超重人群中，MariTide在第52周实现了平均体重减轻约20%，且未出现体重减轻平台期，表明 ...

A new experimental weight loss drug from Amgen — the first in a growing group of drugs aimed at once-a-month injections instead of once a week — helped patients lose up to 20% of their weight in one ...

Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share ...

Amgen's MariTide achieves up to 20% weight loss in mid-stage trial, but analysts were expecting up to 25% Amgen Inc.'s stock closed down 4.8% Tuesday, after the company said a mid-stage trial of its ...

That increased convenience will have to be accompanied by weight loss that is at least as effective as its rivals, and Amgen ...

William Blair's assessment is that MariTide is an improvement on current obesity therapies with a profile that "will be ...

Shares of Amgen (NASDAQ: AMGN) recently ticked lower despite a very positive-sounding press release regarding its weight ...